A Fluorescent Assay for Agonist-Activated Phospholipase D in Mammalian Cell Extracts

Ella, Krishna M.; Meier, Gregor; Bradshaw, Cynthia D.; Huffman, Kim M.; Spivey, Eric C.; Meier, Kathryn E.

doi:10.1006/abio.1994.1152

Cited by 31 publications

(19 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein products were confirmed by Western blot. PLD activity was measured as described previously (56). Briefly, BODIPY-phosphatidylcholine (BPC; Molecular Probes) was dissolved in ethanol to a final concentration of 1 mM.…”

Section: Methodsmentioning

confidence: 99%

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice

Lee¹,

Meier²,

Furuta³

et al. 2012

J. Clin. Invest.

121

187

View full text Add to dashboard Cite

Breast cancers commonly become resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs); however, the mechanisms of this resistance remain largely unknown. We hypothesized that resistance may originate, at least in part, from molecular alterations that activate signaling downstream of EGFR. Using a screen to measure reversion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a candidate cancer-associated gene capable of conferring resistance to EGFR-TKIs. FAM83A overexpression in cancer cells increased proliferation and invasion and imparted EGFR-TKI resistance both in cultured cells and in animals. Tumor cells that survived EGFR-TKI treatment in vivo had upregulated FAM83A levels. Additionally, FAM83A overexpression dramatically increased the number and size of transformed foci in cultured cells and anchorage-independent growth in soft agar. Conversely, FAM83A depletion in cancer cells caused reversion of the malignant phenotype, delayed tumor growth in mice, and rendered cells more sensitive to EGFR-TKI. Analyses of published clinical data revealed a correlation between high FAM83A expression and breast cancer patients' poor prognosis. We found that FAM83A interacted with and caused phosphorylation of c-RAF and PI3K p85, upstream of MAPK and downstream of EGFR. These data provide an additional mechanism by which tumor cells can become EGFR-TKI resistant.

show abstract

Section: Methodsmentioning

confidence: 99%

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice

Lee¹,

Meier²,

Furuta³

et al. 2012

J. Clin. Invest.

121

187

View full text Add to dashboard Cite

show abstract

“…Phospholipase D Assays-The methods used to measure phospholipase D (PLD) activity in intact cells and membrane preparations have been described previously (28,30). Briefly, for the intact cell assay, confluent Rat-1 cells grown in 35-mm dishes were cultured for 18 h in 2 ml of DME containing 5 Ci/ml [ Values are expressed as a percent of the total radioactivity recovered from each dish.…”

Section: Methodsmentioning

confidence: 99%

Synergistic Effects of Insulin and Phorbol Ester on Mitogen-activated Protein Kinase in Rat-1 HIR Cells

Knoepp

Wisehart-Johnson

Buse

et al. 1996

Journal of Biological Chemistry

View full text Add to dashboard Cite

Regulation of the activity of the extracellular signal regulated kinase (ERK) mitogen-activated protein kinases was examined in Rat-1 HIR, a fibroblast cell line overexpressing the human insulin receptor. Insulin or phorbol ester induced partial activations of ERKs, while a combination of insulin and phorbol ester resulted in a synergistic activation. Preincubation with phorbol ester increased the subsequent response to insulin. Phorbol ester did not enhance tyrosine phosphorylation of the insulin receptor. Insulin did not enhance activation of phospholipase D in response to phorbol ester. Lysophosphatidic acid also acted synergistically with insulin to induce ERK activation. Lysophosphatidic acid alone had little effect on ERK, and did not activate phospholipase D. The combination of phorbol ester and insulin maintained tyrosine phosphorylation of focal adhesion kinase, while insulin alone decreased its tyrosine phosphorylation. Phorbol ester induced phosphorylation of Shc on serine/threonine, while insulin induced tyrosine phosphorylation of Shc and Shc-Grb2 binding. These results suggest that full activation of ERKs in fibroblasts can require the cooperation of at least two signaling pathways, one of which may result from a protein kinase C-dependent phosphorylation of effectors regulating ERK activation. In this manner, phorbol esters may enhance mitogenic signals initiated by growth factor receptors.The ERK 1 mitogen-activated protein kinases (MAPKs), which are activated in response to a wide variety of growth factors, hormones, and other mitogenic stimuli, have been linked to the induction of cell proliferation (1). The insulin receptor, a tyrosine kinase, can elicit both metabolic and mitogenic responses (2). The insulin receptor binds to several effectors, with binding to insulin receptor substrate-1 (IRS-1) mediating most of the metabolic effects of insulin. Mutation or deletion of some of the phosphorylatable tyrosines in the insulin receptor can enhance its mitogenic activity (3), suggesting that multifunctionality of the receptor may compromise its mitogenic potential. Phorbol ester tumor promoters can act additively or synergistically with insulin to induce mitogenesis (4, 5).The mitogenic activity of the insulin receptor has been correlated with its ability to activate MAPK, a response that is mediated predominantly through interaction of the insulin receptor with Shc (6). IRS-1 and Shc compete for binding to Grb2, such that IRS-1 may either inhibit (7) or enhance (8) activation of MAPK. Tyrosine-phosphorylated Shc binds to the adapter Grb2, causing disassembly of SOS from Grb2 resulting in GDP-GTP exchange on Ras (9). GTP-bound Ras promotes activation of Raf-1 kinase (1, 10). Raf-1 phosphorylates and activates MEK (mitogen-activated protein kinase kinase/ERK kinase), which phosphorylates and activates MAPK. One downstream effector of MAPK is RSK, another protein serine/threonine kinase. It is clear that the insulin receptor initiates signals that are independent of MAPK activation (reviewed in Ref...

show abstract

“…Most of the PLD activity was membrane-bound, with cytosol producing only 21% of the PBt seen in membranes with equal amounts of cellular protein (data not shown). PBt can be metabolized to lyso-PBt by a calcium-independent PLA 2 in membranes from mammalian cells (18), including PC12K (Fig. 1A).…”

Section: Resultsmentioning

confidence: 99%

“…PC12K (a wild-type cell line) and RG20 (stably transfected with human ␣ 2A/D AR) (21) were grown for 3-5 days in 35-or 100-mm dishes. Cytosolic and membrane extracts were prepared as described (18). Briefly, cells were incubated in culture medium at 37°C, washed, resuspended in lysis buffer (20 mM HEPES (pH 7.5), 80 mM ␤-glycerophosphate, 10 mM EGTA, 2 mM EDTA, and 2 mM dithiothreitol), sonicated, and sedimented at 100,000 ϫ g for 20 min at 4°C.…”

Section: Methodsmentioning

confidence: 99%

Phospholipase D Activity in PC12 Cells

Ella

Chen

McNair

et al. 1997

Journal of Biological Chemistry

View full text Add to dashboard Cite

PC12 neuronal cells express a membrane phospholipase D (PLD) activity that is detected at similar levels in undifferentiated or differentiated cells. The regulation of this activity by agonists was explored. Membrane phospholipase D activity was increased by treatment of cells with the phorbol ester phorbol 12-myristate 13-acetate (PMA) or with nerve growth factor. The ability of PMA to activate PLD was confirmed in intact PC12 cells. Basal activity of PLD in membranes was reduced in RG20, a PC12 cell line overexpressing the human ␣ 2A -adrenergic receptor. PMA did not increase PLD activity in RG20 cells, as assessed both in membrane preparations and in intact cells. Cyclic AMP levels did not regulate phospholipase D activity in either cell type. However, incubation of RG20 cells with the ␣ 2 -adrenergic antagonist rauwolscine or with pertussis toxin increased membrane PLD activity and restored activation of PLD by PMA. These data suggest that the effects of the overexpressed ␣ 2A -adrenergic receptor on PLD activity are mediated by precoupling of the receptor to the heterotrimeric GTP-binding protein, G i , but are independent of adenylate cyclase regulation. The results of this study suggest that membrane phospholipase D activity can be negatively regulated via G i in PC12 cells. Phospholipase D (PLD)1 isoforms have been sequenced from yeast (1-3) and mammalian (4) cells. It appears that more than one form of PLD is expressed in mammals (5-8). PLDs can be activated in response to extracellular signals such as growth factors, hormones, and neurotransmitters (9) and by phorbol esters that stimulate protein kinase C (10). Hydrolysis of phosphatidylcholine (PC) by PLD produces phosphatidic acid (PA). PA is proposed to play a role in signal transduction as a lipid mediator or mediator precursor (11)(12)(13)(14). Some PLDs are regulated by the small GTP-binding proteins . However, the full range of effectors and mediators regulating different isoforms of PLD remains to be elucidated. This laboratory has characterized regulated PLDs in yeast and mammalian cells (10, 18 -20). In this study, we explore the role of a heterotrimeric GTP-binding protein, G i , in the regulation of PLD activity in a neuronal cell line.Signal transduction pathways have been extensively studied in PC12, a rat phaeochromocytoma cell line that can be induced to differentiate to a neuronal phenotype. PC12 transfected with the ␣ 2A -adrenergic receptor (␣ 2A AR) have been used to examine coupling of this receptor to its effectors (21). The ␣ 2A AR couples to the heterotrimeric GTP-binding protein G i , is widely expressed, and mediates the central hypotensive effects of ␣ 2 agonists (22,23). G i proteins are heterotrimeric GTP-binding proteins containing an ␣ i subunit. They are coupled to inhibition of adenylate cyclase as well as to pathways involving additional effectors, such as small GTP-binding proteins (24). In this study, ␣ 2A AR-expressing PC12 cells were used to examine the potential role of G i in regulating PLD activity. MATERIALS AN...

show abstract

A Fluorescent Assay for Agonist-Activated Phospholipase D in Mammalian Cell Extracts

Cited by 31 publications

References 1 publication

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice

Synergistic Effects of Insulin and Phorbol Ester on Mitogen-activated Protein Kinase in Rat-1 HIR Cells

Phospholipase D Activity in PC12 Cells

Contact Info

Product

Resources

About